ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Courts, Congress Likely to Stand in Way of J&J’s Third Texas Two-Step Plan

U.S. Court of Appeals for 3rd Circuit latest to reject unprecedented bankruptcy strategy

Lawyers on behalf of tens of thousands of ovarian cancer victims are calling on Johnson & Johnson (NYSE: JNJ) to end its “war of attrition against cancer victims.”

“The third time will not be the charm for J&J,” says Andy Birchfield, head of the Mass Torts Litigation Section at the Beasley Allen Law Firm, who has been instrumental in helping to foil the first two attempts at bankruptcy by the half-trillion-dollar company. “Recent developments in the courts and in Congress should convince J&J to abandon its strategy and act as a responsible corporation by providing truly fair and reasonable compensation in a non-coercive resolution.”

On Thursday, the U.S. Court of Appeals for the 3rd Circuit reinforced an earlier ruling that J&J could not stash its talc liabilities in a shell subsidiary and then plunge it into bankruptcy to stymie thousands of lawsuits alleging that its talc products caused ovarian cancer and mesothelioma. The court found the bankruptcy was filed in bad faith because the subsidiary, LTL Management, LLC, was not in financial distress.

Earlier this week, a bipartisan group of congressional lawmakers led by Sen. Josh Hawley (R-MO) and Sen. Sheldon Whitehouse (D-RI) introduced legislation to ban the Texas Two-Step. The Ending Corporate Bankruptcy Abuse Act (ECBA) of 2024 would deter the Texas Two-Step and ensure injury victims have a chance to be heard in court. The ECBA would instruct courts to presume a bankruptcy has been filed in bad faith if it is a Texas Two-Step bankruptcy.

“Johnson & Johnson has brought this legislative action upon itself by flouting the law and arrogantly pushing a failed strategy,” says Leigh O’Dell, co-lead counsel for consolidated multidistrict litigation. “The courts and Congress are saying that J&J is not entitled to use the powerful tools of bankruptcy to strip away the rights of cancer victims.”

Friday July 26 is the deadline for talc claimants to approve or reject a third J&J bankruptcy attempt. A settlement plan aimed at ending the litigation must receive 75% of all votes before the company can proceed with another Texas Two-Step maneuver and bankruptcy filing, this time in Texas. Opponents of the plan say that proposed compensation unfairly shortchanges victims and their families, many who have died or suffered for a decade or more.

“For J&J to lose this vote would be akin to Vladimir Putin losing a Russian election,” says Mr. Birchfield. “J&J controls the ballot. J&J determines who can vote and all the rules for voting. J&J controls the agent that counts the ballots and determines which votes will be counted and which ones will be discarded. And this is all done without court supervision.

“However, there is a vast difference between winning the vote through ballot stuffing and succeeding with a bankruptcy plan. This will be J&J’s third attempt to use bankruptcy to shirk its responsibility for its asbestos-laden talc-based baby powder. The egregiousness of J&J’s scheme to use bankruptcy to evade accountability and cap its liability has prompted bipartisan congressional action with a bill that would curb the abuse of J&J’s Texas Two Step.”

Beasley Allen is one of the country’s leading civil litigation firms, holding several national records for verdicts and settlements.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  228.43
+1.08 (0.48%)
AAPL  270.97
-2.70 (-0.99%)
AMD  214.95
+1.52 (0.71%)
BAC  55.88
+0.61 (1.10%)
GOOG  311.33
+2.72 (0.88%)
META  661.50
+2.73 (0.41%)
MSFT  484.92
-1.00 (-0.21%)
NVDA  183.69
+2.70 (1.49%)
ORCL  198.38
+6.41 (3.34%)
TSLA  488.73
+7.53 (1.56%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.